Find Funding Opportunities

This Funding Opportunity Announcement (FOA) solicits Research Program Project Grant (P20) applications from institutions/organizations proposing exploratory collaborative research on disease modification or prevention in an epilepsy syndrome. Successful exploratory studies may lead to subsequent applications for support of a collaborative, multidisciplinary Epilepsy Center without Walls on Disease Modification and Prevention. Depending on the topic area, however, exploratory studies may alternatively lead to applications for the NINDS Translational Program for Resistant Epilepsy and Epileptogenesis, the NINDS Clinical Trials Program, or additional investigator initiated research programs. This FOA is for support of new projects, not continuation of projects that have already been initiated. Interventional clinical trials are also not appropriate for this FOA.

This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) to address different and complementary research needs for the development appropriate pediatric drug formulations in different age groups. This FOA also encourages the development and testing of novel drug delivery systems in the pediatric population. The goal of this FOA is not to duplicate or compete with the private sector but to complement and accelerate the development of appropriate pediatric drugs formulations and drug delivery systems.

This Funding Opportunity Announcement (FOA) invites Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) to address different and complementary research needs for the development appropriate pediatric drug formulations in different age groups. This FOA also encourages the development and testing of novel drug delivery systems in the pediatric population. The goal of this FOA is not to duplicate or compete with the private sector but to complement and accelerate the development of appropriate pediatric drugs formulations and drug delivery systems.

The goal of this funding opportunity announcement (FOA) is to support preclinical development and testing of new therapies for neurological disorders. The program will facilitateencouragement, development, and review of therapy-directed projects to accelerate the translation of basic research discoveries into therapeutic candidates for clinical testing. To be eligible for support, projects must include therapeutic leads and in vivo proof of concept on efficacy. The program supports preclinical optimization and testing of the leads, and projects must be sufficiently advanced that an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application to the Food and Drug Administration (FDA) can be submitted by the end of the project period. The program does not support early-stage therapeutic discovery activities such as screening. The program also excludes clinical research, basic research, and studies of disease mechanism. The scope includes only therapy development activities, so development of diagnostics, biomarkers, or rehabilitation strategies cannot be supported. This is a milestone-driven cooperative agreement program involving participation of NINDS staff in the development of the project plan and monitoring of research progress.

The goal of this Funding Opportunity Announcement (FOA) is to support preliminary steps in the preclinical development of therapeutics for neurological disorders. Such projects, if successful, should lead directly to a subsequent project that will include all remaining activities for submission of an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application to the Food and Drug Administration (FDA). The scope includes only therapy development activities, so development of diagnostics, biomarkers, or rehabilitation strategies cannot be supported. Clinical research, basic research, and studies of disease mechanism are outside program scope.

The goal of this funding opportunity announcement (FOA) is to support preclinical development and testing of new therapies for neurological disorders. The program will facilitate encouragementation, development, and review of therapy-directed projects to accelerate the translation of basic research discoveries into therapeutic candidates for clinical testing. Phase II and Fast-Track SBIR cooperative agreements are supported under the program. Phase I, as part of a Fast-Track, supports preliminary steps in the process for the preclinical development of therapeutics. To be eligible for Phase II support, either based on a previously successful Phase I or as part of a Fast-Track, projects must include therapeutic leads and in vivo proof of concept on efficacy. Phase II supports preclinical optimization and testing of the leads, and projects must be sufficiently advanced that an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application to the Food and Drug Administration (FDA) can be submitted by the end of the project period. Phase II cannot support early-stage therapeutic discovery activities such as screening. The program scope excludes clinical research, basic research, and studies of disease mechanism. The scope includes only therapy development activities, so development of diagnostics, biomarkers, or rehabilitation strategies cannot be supported. This is a milestone-driven SBIR cooperative agreement program involving participation of NINDS staff in the development of the project plan and monitoring of research progress.

The goal of this funding opportunity announcement (FOA) is to support preclinical development and testing of new therapies for neurological disorders. The program will facilitate encouragement , development, and review of therapy-directed projects to accelerate the translation of basic research discoveries into therapeutic candidates for clinical testing. To be eligible for support, projects must include therapeutic leads and in vivo proof of concept on efficacy. The program supports preclinical optimization and testing of the leads, and projects must be sufficiently advanced that an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application to the Food and Drug Administration (FDA) can be submitted by the end of the project period. The program does not support early-stage therapeutic discovery activities such as screening. The program also excludes clinical research, basic research, and studies of disease mechanism. The scope includes only therapy development activities, so development of diagnostics, biomarkers, or rehabilitation strategies cannot be supported. This is a milestone-driven cooperative agreement program involving participation of NINDS staff in the development of the project plan and monitoring of research progress.

The National Institute on Aging (NIA), and the National Institute of Neurological Disorders and Stroke (NINDS), working in part with funds contributed by the John A. Hartford Foundation (http://www.jhartfound.org/) and The American Federation for Aging Research (http://afar.org/), are pursuing this initiative to encourage and assist the development of future leaders in the field of aging by supporting clinically trained (primarily physician) faculty members early in their careers to gain additional research training and to establish independent programs in aging research.

The National Institute on Aging (NIA) and the National Institute of Neurological Disorders and Stroke (NINDS), working in part with funds contributed by the John A. Hartford Foundation (http://www.jhartfound.org/) and The American Federation for Aging Research (http://afar.org/), are pursuing this initiative to encourage and assist the development of future leaders in the field of aging by supporting clinically trained (primarily physician) faculty members early in their careers to gain additional research training and to establish independent programs in aging research.

The National Institutes of Health (NIH) Investigator-Initiated Small Research Grant (R03) funding opportunity supports small research projects that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.